VIVO
Get informed when a big investor buys or sells
+ FollowUndervalued by 500% based on the discounted cash flow analysis.
| Market cap | $104.77 Million |
|---|---|
| Enterprise Value | $62.92 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $- |
| Beta | -1.07 |
| Outstanding Shares | - |
| P/E Ratio | 6.47 |
|---|---|
| PEG | -2.2 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.21 |
| Enterprise Value to EBIT | 2.41 |
| Enterprise Value to Net Income | -24 |
| Total Debt to Enterprise | 0.51 |
| Debt to Equity | 0.09 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Controls taxation and entitlement spending (like Medicare/Medicaid reimbursements), which profoundly impacts the financial viability and customer base for medical instrument manufacturers.
Determines specific federal spending allocations for healthcare programs, research (e.g., NIH), and agencies (e.g., VA) that directly purchase or influence the demand for medical instruments.
Direct oversight of the FDA, which regulates the approval, manufacturing, and marketing of medical instruments, and influences labor policies affecting production costs.
Critical for intellectual property protection (patents) and antitrust enforcement, both highly relevant for medical device innovation, competition, and potential industry consolidation.
Directly influences funding for the Department of Veterans Affairs, a significant federal purchaser of medical devices and supplies relevant to Meridian Bioscience.